SRRK — Scholar Rock Holding Share News
0.000.00%
Last trade - 00:00Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP-eBay, Sunbelt Rentals, T-Mobile
U.S. RESEARCH ROUNDUP-Eli Lilly, McDonald's, Welltower
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
Scholar Rock says its first muscle-targeted SMA therapy will cost about $310,000 annually (updated)
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
Scholar Rock gains on FDA approval for first muscle-targeted SMA treatment
NASDAQ RESUMED AT 06:45 PM
Brief: Scholar Rock Holding Corporation - ISEMBYLD US Commercial Launch Underway Product Available To Ship In Coming Days
Corrected: UPDATE 3-Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11)
Brief: US FDA - Approves Isembyld For Spinal Muscular Atrophy In Patients Aged 2 Years And Older
US FDA approves Scholar Rock's muscle weakness drug